XML 46 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 4 Months Ended | 8 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2024 | Aug. 31, 2024 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  |  | Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Act and Item 402(v) of Regulation S-K promulgated by the SEC, the Company is providing information about the relationship between executive compensation actually paid to our Principal Executive Officers (each, a “PEO”), and the other NEOs (as calculated in accordance with 402(v) of Regulation S-K) and certain financial performance measures. For fiscal years 2020 through 2023, Mr. Hunt was the PEO. For 2024, Mr. Hunt served as PEO until August 31, 2024 and Mr. Loeillot served as PEO beginning on September 1, 2024. For additional information on the Company’s compensation programs and philosophy and how the Company designs its compensation programs to align pay with performance, see the section titled “Compensation Discussion and Analysis – Compensation Objectives” on page 35. Pay Versus Performance Table
|  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based On: |  |
Year | Summary Compensation on Table Total for PEO Tony J. Hunt ($) | Compensation Actually Paid to PEO Tony J. Hunt ($)(1) | Summary Compensation on Table Total for PEO Olivier Loeillot ($) | Compensation Actually Paid to PEO Olivier Loeillot ($)(1) | Average Summary Compensation Table Total for Non-PEO NEOs ($) |  | Average Compensation Actually Paid to Non-PEO NEOs ($)(2) |  | Total Shareholder Return ($)(3) | Peer Group Total Shareholder Return ($)(4) | Net Income ($)(5) | Adjusted Revenue ($)(6)
2024 | 20,304,850 | 921,139 | 7,184,359 | 5,125,639 | 2,239,292 | (7) | 1,089,794 | (7) | 156 | 114 | (25,514,078) | 634,836,884
2023 | 7,929,275 | 8,199,283 | N/A | N/A | 2,783,824 | (8) | 2,838,303 | (8) | 194 | 115 | 41,577,200 | 632,862,757
2022 | 7,713,930 | (14,037,928) | N/A | N/A | 2,030,204 | (9) | 373,690 | (9) | 183 | 111 | 185,958,784 | 823,421,806
2021 | 7,765,070 | 28,761,887 | N/A | N/A | 1,903,210 | (9) | 3,095,727 | (9) | 286 | 125 | 128,290,831 | 666,832,455
2020 | 5,066,061 | 36,587,864 | N/A | N/A | 1,660,855 | (10) | 4,883,849 | (10) | 207 | 126 | 59,925,688 | 360,009,590
(1) The amounts reported represent the “compensation actually paid” to our CEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to the CEO in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the amount reported for the CEO in the “Total” column of the Summary Compensation Table for each year to calculate compensation actually paid:
Year |  | Summary Compensation Table Total for PEO ($) |  |  | Summary Compensation Table Value of Equity Awards ($)(a) |  |  | Equity Award Adjustments ($)(b) |  |  | Compensation Actually Paid to PEO ($) |
2024 (Loeillot) |  |  | 7,184,359 |  |  |  | (6,034,734 | ) |  |  | 3,976,014 |  |  |  | 5,125,639 |
2024 (Hunt) |  |  | 20,304,850 |  |  |  | (18,913,711 | ) |  |  | (470,000 | ) |  |  | 921,139 |
2023 |  |  | 7,929,275 |  |  |  | (7,044,275 | ) |  |  | 7,314,283 |  |  |  | 8,199,283 |
2022 |  |  | 7,713,930 |  |  |  | (6,123,490 | ) |  |  | (15,628,368 | ) |  |  | (14,037,928 | )
2021 |  |  | 7,765,070 |  |  |  | (5,663,515 | ) |  |  | 26,660,332 |  |  |  | 28,761,887 |
2020 |  |  | 5,066,061 |  |  |  | (3,957,311 | ) |  |  | 35,479,114 |  |  |  | 36,587,864 |
(a) The amounts reported represent the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for the applicable year. (b) The amounts deducted or added in calculating the equity award adjustments are as follows and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant:
Year |  | Year End Fair Value of Equity Awards ($) |  |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) |  |  | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) |  |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) |  |  | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) |  |  | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation ($) |  |  | Total Equity Award Adjustments ($) |
2024 (Loeillot) |  |  | 5,263,849 |  |  |  | (1,022,566 | ) |  |  | — |  |  |  | (265,269 | ) |  |  | — |  |  |  | — |  |  |  | 3,976,014 |
2024 (Hunt) |  |  | 5,112,360 |  |  |  | (5,107,473 | ) |  |  | — |  |  |  | (84,234 | ) |  |  | (390,653 | ) |  |  | — |  |  |  | (470,000 | )
2023 |  |  | 5,286,030 |  |  |  | 1,518,601 |  |  |  | — |  |  |  | 509,652 |  |  |  | — |  |  |  | — |  |  |  | 7,314,283 |
2022 |  |  | 5,089,051 |  |  |  | (16,700,137 | ) |  |  | — |  |  |  | (4,017,282 | ) |  |  | — |  |  |  | — |  |  |  | (15,628,368 | )
2021 |  |  | 5,871,874 |  |  |  | 18,454,854 |  |  |  | — |  |  |  | 2,333,604 |  |  |  | — |  |  |  | — |  |  |  | 26,660,332 |
2020 |  |  | 8,611,644 |  |  |  | 27,291,322 |  |  |  | — |  |  |  | (423,852 | ) |  |  | — |  |  |  | — |  |  |  | 35,479,114 |
(2) The amounts reported represent the average “compensation actually paid” to the NEOs other than the PEO(s) as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the average of the amounts reported in the “Total” column of the Summary Compensation Table for the NEOs as a group (excluding the PEO(s)) for each year to determine the compensation actually paid, using the same methodology described above in footnote 1:
Year |  | Average Reported Summary Compensation Table Total for Non-PEO NEOs ($) |  |  | Average Summary Compensation Table Value of Equity Awards ($)(a) |  |  | Average Equity Award Adjustments ($)(b) |  |  | Average Compensation Actually Paid to Non-PEO NEOs ($) |
2024 |  |  | 2,239,292 |  |  |  | (1,473,458 | ) |  |  | 323,960 |  |  |  | 1,089,794 |
2023 |  |  | 2,783,824 |  |  |  | (2,208,580 | ) |  |  | 2,263,059 |  |  |  | 2,838,303 |
2022 |  |  | 2,030,204 |  |  |  | (1,293,539 | ) |  |  | (362,975 | ) |  |  | 373,690 |
2021 |  |  | 1,903,210 |  |  |  | (1,158,499 | ) |  |  | 2,351,016 |  |  |  | 3,095,727 |
2020 |  |  | 1,660,855 |  |  |  | (991,336 | ) |  |  | 4,214,330 |  |  |  | 4,883,849 |
(a) The amounts reported represent the average of the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable fiscal year. (b) The amounts deducted or added in calculating for equity award adjustments are as follows:
Year |  | Year End Fair Value of Equity Awards ($) |  |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) |  |  | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) |  |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) |  |  | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) |  |  | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation ($) |  |  | Total Equity Award Adjustments ($) |
2024 |  |  | 1,003,993 |  |  |  | (522,318 | ) |  |  | — |  |  |  | (105,501 | ) |  |  | (52,214 | ) |  |  | — |  |  |  | 323,960 |
2023 |  |  | 1,898,736 |  |  |  | 61,717 |  |  |  | — |  |  |  | 29,510 |  |  |  | 273,096 |  |  |  | — |  |  |  | 2,263,059 |
2022 |  |  | 972,047 |  |  |  | (895,955 | ) |  |  | — |  |  |  | (426,369 | ) |  |  | (12,698 | ) |  |  | — |  |  |  | (362,975 | )
2021 |  |  | 1,240,869 |  |  |  | 923,948 |  |  |  | — |  |  |  | 186,199 |  |  |  | — |  |  |  | — |  |  |  | 2,351,016 |
2020 |  |  | 2,164,711 |  |  |  | 1,959,514 |  |  |  | — |  |  |  | 90,105 |  |  |  | — |  |  |  | — |  |  |  | 4,214,330 |
(3) Total shareholder return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. (4) Represents the weighted peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index, a published industry index. (5) The dollar amounts reported represent the amount of net income reflected in the Company’s audited consolidated financial statements for the applicable fiscal year. (6) Adjusted revenue is defined as the Company’s total consolidated revenue as reported under U.S. generally accepted accounting principles (“GAAP”) adjusted to reflect the impact of acquisitions and the change in foreign exchange rates. In 2024, the total as-reported consolidated revenue of $634.4 million was adjusted favorably by $0.4 million, resulting in adjusted revenue of $634.8 million. In 2023, the total as-reported consolidated revenue of $638.8 million was adjusted unfavorably by $5.9 million, resulting in adjusted revenue of $632.9 million. In 2022, the total as-reported consolidated revenue of $801.5 million was adjusted favorably by $21.9 million, resulting in adjusted revenue of $823.4 million. In 2021, the total as-reported consolidated revenue of $670.5 million was adjusted (decreased) by $3.7 million, resulting in adjusted revenue of $666.8 million. While the Company considers numerous financial and non-financial performance measures for the purpose of evaluating and determining executive compensation, the Company considers adjusted revenue, which is one of the Corporate Objectives (along with adjusted EPS) used to determine annual cash incentive compensation paid to the NEOs for fiscal year 2024, to be the most important financial performance measure used to link compensation actually paid to Company performance for fiscal year 2024. (7) Non-PEO NEOs for 2024 include Mr. Garland, Mr. Bylund, Mr. Kuriyel, and Ms. Gebski. (8) Non-PEO NEOs for 2023 include Mr. Garland, Mr. Bylund, Ms. Gebski, Mr. Kuriyel, Mr. Loeillot and Mr. Snodgres. (9) Non-PEO NEOs for 2021 and 2022 include Mr. Snodgres, Mr. Bylund, Ms. Gebski and Mr. Kuriyel. (10) Non-PEO NEOs for 2020 include Mr. Snodgres and Mr. Kuriyel. |  |  |  |
Company Selected Measure Name |  |  | AdjustedRevenue |  |  |  |
Named Executive Officers, Footnote |  |  | Non-PEO NEOs for 2024 include Mr. Garland, Mr. Bylund, Mr. Kuriyel, and Ms. Gebski. | Non-PEO NEOs for 2023 include Mr. Garland, Mr. Bylund, Ms. Gebski, Mr. Kuriyel, Mr. Loeillot and Mr. Snodgres. | Non-PEO NEOs for 2021 and 2022 include Mr. Snodgres, Mr. Bylund, Ms. Gebski and Mr. Kuriyel. | Non-PEO NEOs for 2021 and 2022 include Mr. Snodgres, Mr. Bylund, Ms. Gebski and Mr. Kuriyel. | (10) Non-PEO NEOs for 2020 include Mr. Snodgres and Mr. Kuriyel.
Peer Group Issuers, Footnote |  |  | Represents the weighted peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index, a published industry index. |  |  |  |
PEO Total Compensation Amount |  |  |  | $ 7,929,275 | $ 7,713,930 | $ 7,765,070 | $ 5,066,061
PEO Actually Paid Compensation Amount |  |  |  | 8,199,283 | (14,037,928) | 28,761,887 | 36,587,864
Adjustment To PEO Compensation, Footnote |  |  | (1) The amounts reported represent the “compensation actually paid” to our CEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to the CEO in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the amount reported for the CEO in the “Total” column of the Summary Compensation Table for each year to calculate compensation actually paid:
Year |  | Summary Compensation Table Total for PEO ($) |  |  | Summary Compensation Table Value of Equity Awards ($)(a) |  |  | Equity Award Adjustments ($)(b) |  |  | Compensation Actually Paid to PEO ($) |
2024 (Loeillot) |  |  | 7,184,359 |  |  |  | (6,034,734 | ) |  |  | 3,976,014 |  |  |  | 5,125,639 |
2024 (Hunt) |  |  | 20,304,850 |  |  |  | (18,913,711 | ) |  |  | (470,000 | ) |  |  | 921,139 |
2023 |  |  | 7,929,275 |  |  |  | (7,044,275 | ) |  |  | 7,314,283 |  |  |  | 8,199,283 |
2022 |  |  | 7,713,930 |  |  |  | (6,123,490 | ) |  |  | (15,628,368 | ) |  |  | (14,037,928 | )
2021 |  |  | 7,765,070 |  |  |  | (5,663,515 | ) |  |  | 26,660,332 |  |  |  | 28,761,887 |
2020 |  |  | 5,066,061 |  |  |  | (3,957,311 | ) |  |  | 35,479,114 |  |  |  | 36,587,864 |
(a) The amounts reported represent the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for the applicable year. (b) The amounts deducted or added in calculating the equity award adjustments are as follows and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant:
Year |  | Year End Fair Value of Equity Awards ($) |  |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) |  |  | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) |  |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) |  |  | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) |  |  | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation ($) |  |  | Total Equity Award Adjustments ($) |
2024 (Loeillot) |  |  | 5,263,849 |  |  |  | (1,022,566 | ) |  |  | — |  |  |  | (265,269 | ) |  |  | — |  |  |  | — |  |  |  | 3,976,014 |
2024 (Hunt) |  |  | 5,112,360 |  |  |  | (5,107,473 | ) |  |  | — |  |  |  | (84,234 | ) |  |  | (390,653 | ) |  |  | — |  |  |  | (470,000 | )
2023 |  |  | 5,286,030 |  |  |  | 1,518,601 |  |  |  | — |  |  |  | 509,652 |  |  |  | — |  |  |  | — |  |  |  | 7,314,283 |
2022 |  |  | 5,089,051 |  |  |  | (16,700,137 | ) |  |  | — |  |  |  | (4,017,282 | ) |  |  | — |  |  |  | — |  |  |  | (15,628,368 | )
2021 |  |  | 5,871,874 |  |  |  | 18,454,854 |  |  |  | — |  |  |  | 2,333,604 |  |  |  | — |  |  |  | — |  |  |  | 26,660,332 |
2020 |  |  | 8,611,644 |  |  |  | 27,291,322 |  |  |  | — |  |  |  | (423,852 | ) |  |  | — |  |  |  | — |  |  |  | 35,479,114 |
Non-PEO NEO Average Total Compensation Amount |  |  | $ 2,239,292 | 2,783,824 | 2,030,204 | 1,903,210 | 1,660,855
Non-PEO NEO Average Compensation Actually Paid Amount |  |  | $ 1,089,794 | 2,838,303 | 373,690 | 3,095,727 | 4,883,849
Adjustment to Non-PEO NEO Compensation Footnote |  |  | (2) The amounts reported represent the average “compensation actually paid” to the NEOs other than the PEO(s) as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the average of the amounts reported in the “Total” column of the Summary Compensation Table for the NEOs as a group (excluding the PEO(s)) for each year to determine the compensation actually paid, using the same methodology described above in footnote 1:
Year |  | Average Reported Summary Compensation Table Total for Non-PEO NEOs ($) |  |  | Average Summary Compensation Table Value of Equity Awards ($)(a) |  |  | Average Equity Award Adjustments ($)(b) |  |  | Average Compensation Actually Paid to Non-PEO NEOs ($) |
2024 |  |  | 2,239,292 |  |  |  | (1,473,458 | ) |  |  | 323,960 |  |  |  | 1,089,794 |
2023 |  |  | 2,783,824 |  |  |  | (2,208,580 | ) |  |  | 2,263,059 |  |  |  | 2,838,303 |
2022 |  |  | 2,030,204 |  |  |  | (1,293,539 | ) |  |  | (362,975 | ) |  |  | 373,690 |
2021 |  |  | 1,903,210 |  |  |  | (1,158,499 | ) |  |  | 2,351,016 |  |  |  | 3,095,727 |
2020 |  |  | 1,660,855 |  |  |  | (991,336 | ) |  |  | 4,214,330 |  |  |  | 4,883,849 |
(a) The amounts reported represent the average of the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable fiscal year. (b) The amounts deducted or added in calculating for equity award adjustments are as follows:
Year |  | Year End Fair Value of Equity Awards ($) |  |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) |  |  | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) |  |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) |  |  | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) |  |  | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation ($) |  |  | Total Equity Award Adjustments ($) |
2024 |  |  | 1,003,993 |  |  |  | (522,318 | ) |  |  | — |  |  |  | (105,501 | ) |  |  | (52,214 | ) |  |  | — |  |  |  | 323,960 |
2023 |  |  | 1,898,736 |  |  |  | 61,717 |  |  |  | — |  |  |  | 29,510 |  |  |  | 273,096 |  |  |  | — |  |  |  | 2,263,059 |
2022 |  |  | 972,047 |  |  |  | (895,955 | ) |  |  | — |  |  |  | (426,369 | ) |  |  | (12,698 | ) |  |  | — |  |  |  | (362,975 | )
2021 |  |  | 1,240,869 |  |  |  | 923,948 |  |  |  | — |  |  |  | 186,199 |  |  |  | — |  |  |  | — |  |  |  | 2,351,016 |
2020 |  |  | 2,164,711 |  |  |  | 1,959,514 |  |  |  | — |  |  |  | 90,105 |  |  |  | — |  |  |  | — |  |  |  | 4,214,330 |
Compensation Actually Paid vs. Total Shareholder Return |  |  | Compensation Actually Paid and Company TSR The graph below describes the relationship between compensation actually paid to the PEOs and the average compensation actually paid to the Company’s other NEOs to the Company’s TSR over the five-year period from December 31, 2019 to December 31, 2024, assuming an initial investment of $100 on December 31, 2019. As the graph shows, this relationship is generally aligned in large part because a significant portion of the compensation actually paid to the Company’s NEOs is in the form of equity awards, the value of which is impacted by the stock price changes. |  |  |  |
Compensation Actually Paid vs. Net Income |  |  | Compensation Actually Paid and Net Income The graph below shows the relationship between compensation actually paid to our PEOs and the average compensation actually paid to the Company’s other NEOs to the Company’s net income for the five years presented in the Pay Versus Performance Table. The Company does not use net income as a performance measure in its executive compensation program. |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  | Compensation Actually Paid and Adjusted Revenue The graph below shows the relationship between compensation actually paid to our PEOs and the average compensation actually paid to the Company’s other NEOs to the Company’s adjusted revenue for the five years presented in the Pay Versus Performance Table. As described above, adjusted revenue is defined as the Company’s total consolidated revenue as reported under GAAP, adjusted to reflect the impact of acquisitions. While the Company uses numerous financial and non-financial performance measures in its compensation programs, the Company has determined that adjusted revenue is the most important performance measure used to link compensation actually paid to the Company’s NEOs for fiscal year 2024 to Company performance. The Company uses adjusted revenue (along with adjusted EPS, both of which are weighted equally) as one of the Corporate Objectives in the Company’s short-term incentive compensation program. |  |  |  |
Total Shareholder Return Vs Peer Group |  |  | Total Shareholder Return The graph below describes the relationship between Repligen Corporation’s (Nasdaq: RGEN) TSR and the TSR for the Nasdaq Biotechnology index: RGEN TSR vs. Nasdaq Biotechnology Index |  |  |  |
Tabular List, Table |  |  | Tabular List of Performance Measures The following table includes financial performance measures that the Company has determined are its most important financial performance measures for 2024 and how they were used in relation to executive compensation:
Financial Measure |  | Application in Most Recently Completed Fiscal Year’s Compensation
Adjusted revenue |  | Annual Cash Incentive Compensation – Corporate Objectives
Adjusted EPS |  | Annual Cash Incentive Compensation – Corporate Objectives
Adjusted ROIC |  | Long-term Incentive Plan – PSU Portion (3-year goal)
Base Organic Growth |  | Long-term Incentive Plan – PSU Portion (3-year goal)
Total Shareholder Return Amount |  |  | $ 156 | 194 | 183 | 286 | 207
Peer Group Total Shareholder Return Amount |  |  | 114 | 115 | 111 | 125 | 126
Net Income (Loss) |  |  | $ (25,514,078) | $ 41,577,200 | $ 185,958,784 | $ 128,290,831 | $ 59,925,688
Company Selected Measure Amount |  |  | 634,836,884 | 632,862,757 | 823,421,806 | 666,832,455 | 360,009,590
PEO Name | Mr. Loeillot | Mr. Hunt |  | Mr. Hunt | Mr. Hunt | Mr. Hunt | Mr. Hunt
Additional 402(v) Disclosure |  |  | Description of Relationship Between Compensation Actually Paid and Selected Performance Metrics As described above in the section titled “Compensation and Discussion Analysis – Compensation Objectives” on page 35, the Company’s compensation program is designed to attract and retain high-performing talent in the bioprocessing industry, motivate the Company’s executive officers to create long-term, enhanced shareholder value, and provide a fair reward for executive effort and stimulate professional and personal growth. The Company uses several performance measures to align executive compensation with Company performance, not all of which are presented in the Pay Versus Performance Table above. Moreover, the Company calculates compensation to the PEO and other NEOs on a basis different than the amount reported in the Summary Compensation Table and compensation actually paid, as calculated in accordance with Item 402(v) of Regulation S-K, is not considered by the Board and the Compensation Committee in evaluating or determining executive compensation. In addition, the Board and the Compensation Committee do not use TSR or net income as performance measures when making pay compensation decisions. In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between compensation actually paid and the financial performance metrics presented in the Pay Versus Performance Table. |  |  |  |
Total Company Selected Measure Amount |  |  | $ 634,400,000 | $ 638,800,000 | $ 801,500,000 | $ 670,500,000 |
Company Selected Measure Amount Adjusted (Decreased) |  |  |  |  |  | 3,700,000 |
Impact on Consolidated Revenue |  |  | $ 400,000 | 5,900,000 | 21,900,000 |  |
Measure:: 1 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Adjusted revenue |  |  |  |
Measure:: 2 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Adjusted EPS |  |  |  |
Measure:: 3 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Adjusted ROIC |  |  |  |
Measure:: 4 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Base Organic Growth |  |  |  |
Tony J. Hunt [Member] |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
PEO Total Compensation Amount |  | $ 20,304,850 |  | 7,929,275 | 7,713,930 | 7,765,070 | $ 5,066,061
PEO Actually Paid Compensation Amount |  | 921,139 |  | 8,199,283 | (14,037,928) | 28,761,887 | 36,587,864
Olivier Loeillot [Member] |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
PEO Total Compensation Amount | $ 7,184,359 |  |  |  |  |  |
PEO Actually Paid Compensation Amount | 5,125,639 |  |  |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (7,044,275) | (6,123,490) | (5,663,515) | (3,957,311)
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 7,314,283 | (15,628,368) | 26,660,332 | 35,479,114
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 5,286,030 | 5,089,051 | 5,871,874 | 8,611,644
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 1,518,601 | (16,700,137) | 18,454,854 | 27,291,322
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 509,652 | (4,017,282) | 2,333,604 | (423,852)
PEO | Tony J. Hunt [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | (18,913,711) |  |  |  |  |
PEO | Tony J. Hunt [Member] | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | (470,000) |  |  |  |  |
PEO | Tony J. Hunt [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | 5,112,360 |  |  |  |  |
PEO | Tony J. Hunt [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | (5,107,473) |  |  |  |  |
PEO | Tony J. Hunt [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | (84,234) |  |  |  |  |
PEO | Tony J. Hunt [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  | $ (390,653) |  |  |  |  |
PEO | Olivier Loeillot [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount | (6,034,734) |  |  |  |  |  |
PEO | Olivier Loeillot [Member] | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 3,976,014 |  |  |  |  |  |
PEO | Olivier Loeillot [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 5,263,849 |  |  |  |  |  |
PEO | Olivier Loeillot [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount | (1,022,566) |  |  |  |  |  |
PEO | Olivier Loeillot [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount | $ (265,269) |  |  |  |  |  |
Non-PEO NEO | Equity Awards Adjustments |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ 323,960 | 2,263,059 | (362,975) | 2,351,016 | 4,214,330
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (1,473,458) | (2,208,580) | (1,293,539) | (1,158,499) | (991,336)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 1,003,993 | 1,898,736 | 972,047 | 1,240,869 | 2,164,711
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (522,318) | 61,717 | (895,955) | 923,948 | 1,959,514
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (105,501) | 29,510 | (426,369) | $ 186,199 | $ 90,105
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ (52,214) | $ 273,096 | $ (12,698) |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v + Details
Name: | ecd_Additional402vDisclosureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Company Selected Measure Amount Adjusted Decreased + References No definition available. + Details
Name: | rgen_CompanySelectedMeasureAmountAdjustedDecreased
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Impact On Consolidated Revenue + References No definition available. + Details
Name: | rgen_ImpactOnConsolidatedRevenue
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total Company Selected Measure Amount + References No definition available. + Details
Name: | rgen_TotalCompanySelectedMeasureAmount
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=rgen_TonyJHuntMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=rgen_OlivierLoeillotMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |